142 related articles for article (PubMed ID: 17113239)
1. Targeting SERCA2a as an innovative approach to the therapy of congestive heart failure.
Ferrari P; Micheletti R; Valentini G; Bianchi G
Med Hypotheses; 2007; 68(5):1120-5. PubMed ID: 17113239
[TBL] [Abstract][Full Text] [Related]
2. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
3. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
[TBL] [Abstract][Full Text] [Related]
4. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
6. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
7. Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function.
Arici M; Ferrandi M; Barassi P; Hsu SC; Torre E; Luraghi A; Ronchi C; Chang GJ; Peri F; Ferrari P; Bianchi G; Rocchetti M; Zaza A
J Pharmacol Exp Ther; 2023 Jan; 384(1):231-244. PubMed ID: 36153005
[TBL] [Abstract][Full Text] [Related]
8. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
9. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases.
Kawase Y; Hajjar RJ
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):554-65. PubMed ID: 18665137
[TBL] [Abstract][Full Text] [Related]
10. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
11. Selective SERCA2a activator as a candidate for chronic heart failure therapy.
Arici M; Hsu SC; Ferrandi M; Barassi P; Ronchi C; Torre E; Luraghi A; Chang GJ; Ferrari P; Bianchi G; Peri F; Zaza A; Rocchetti M
J Transl Med; 2024 Jan; 22(1):77. PubMed ID: 38243248
[TBL] [Abstract][Full Text] [Related]
12. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
13. SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications.
Huang CL
Br J Pharmacol; 2013 Oct; 170(3):486-8. PubMed ID: 23822610
[TBL] [Abstract][Full Text] [Related]
14. Factors controlling the activity of the SERCA2a pump in the normal and failing heart.
Vandecaetsbeek I; Raeymaekers L; Wuytack F; Vangheluwe P
Biofactors; 2009; 35(6):484-99. PubMed ID: 19904717
[TBL] [Abstract][Full Text] [Related]
15. Istaroxime in heart failure new hope or more hype.
Dec GW
J Am Coll Cardiol; 2008 Jun; 51(23):2286-8. PubMed ID: 18534277
[No Abstract] [Full Text] [Related]
16. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
17. Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure.
Avvisato R; Jankauskas SS; Santulli G
J Pharmacol Exp Ther; 2023 Jan; 384(1):227-230. PubMed ID: 36581352
[No Abstract] [Full Text] [Related]
18. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
Gheorghiade M; Sabbah HN
Am J Cardiol; 2007 Jan; 99(2A):1A-3A. PubMed ID: 17239700
[No Abstract] [Full Text] [Related]
19. Increased cardiomyocyte function and Ca2+ transients in mice during early congestive heart failure.
Mørk HK; Sjaastad I; Sande JB; Periasamy M; Sejersted OM; Louch WE
J Mol Cell Cardiol; 2007 Aug; 43(2):177-86. PubMed ID: 17574269
[TBL] [Abstract][Full Text] [Related]
20. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
